CD276 autologous chimeric antigen receptor T cells

CD276 autologous chimeric antigen receptor (CAR) T cells are a form of cell therapy in which a patient's own T lymphocytes are genetically engineered to express a synthetic receptor targeting the tumor-associated antigen CD276 (also known as B7-H3). The engineered T cells recognize and bind to CD276 on the surface of cancer cells via their single-chain variable fragment (scFv), leading to activation and proliferation of the modified T cells. Upon engagement with target-expressing tumor cells, these CAR-Ts mediate anti-tumor effects through cytokine secretion and direct cytolytic activity. Preclinical studies have demonstrated potent activity against various solid tumors such as pancreatic cancer and acute myeloid leukemia[5][7]. The mechanism of action is based on specific recognition and killing of tumor cells expressing high levels of CD276 while sparing normal tissues[1][2][5]. This approach is under investigation for multiple solid tumors due to the overexpression of CD276 in many malignancies.

Other names

B7-H3 CAR-TB-7-H3 CAR-TB 7-H3 CAR-TCD276-targeted CAR-T cellsCD-276-targeted CAR-T cellsCD 276-targeted CAR-T cells